Agomelatine Treatment with Adolescents with ADHD

Autor/in	Niederhofer, Helmut
Titel	Agomelatine Treatment with Adolescents with ADHD
Quelle	In: Journal of Attention Disorders, 16 (2012) 6, S. 530-532 PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1087-0547
DOI	10.1177/1087054711423631
Schlagwörter	Forschungsbericht; Adolescents; Sleep; Attention Deficit Hyperactivity Disorder; Patients; Drug Therapy; Stimulants; Correlation; Outcomes of Treatment + Suchen Sie Ihr Suchwort? Adolescent; Adolescence; Adoleszenz; Jugend; Jugendalter; Jugendlicher; Schlaf; Patient; Droge; Korrelation
Abstract	Objective: Antidepressants, in particular Atomextine, along with stimulants have demonstrated benefit in the treatment of ADHD. Agomelatine is a new antidepressant with additional affinities to the melatonergic system. As ADHD has been associated with sleep disorders, it is assumed that Agomelatiine might serve as a therapeutic alternative to treat patients with the ADHD refractory to first line medications. Method: Ten late adolescents were evaluated in a placebo controlled manner. Results: Agomelatine's effect was superior to that of placebo but appeared to be less than that of first line medications such as methylphenidate. Conclusion: Agomelatine may be a useful second line medication for individuals with ADHD, particularly if they suffer from additional sleep disorders. (Contains 1 table.) (As Provided).
Anmerkungen	SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: http://sagepub.com
Begutachtung	Peer reviewed
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10